A-DIFLUOROMETHYLORNITHINE IN PATIENTS WITH ADVANCED BREAST CANCER

Project: Research project

Project Details

Description

Polyamine metabolism appears to be important in the proliferation of cancewr cells and the carcinogenic process. Alpha-difluoromethylornithine (DFMO) interferes with polyamine biosynthesis. Preclinical and clinical data indicate DFMO can inhibit ornithine decarboxylase (ODC), the first rate-limiting enzyme in the activation of the polyamine pathway. Increased ODC activity has been shown to be an important prognostic factor for survival in breast cancer specimens taken directly from patients. This study proposes to evaluate DFMO in patients with hormone refractory advanced breast cancer.
StatusFinished
Effective start/end date10/1/979/30/99

Funding

  • National Center for Research Resources

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.